MODERNA INC (MRNA) Stock Price, Quote, News and Overview
NASDAQ:MRNA - Nasdaq - US60770K1079 - Common Stock - Currency: USD
MRNA Quote, Performance and Key Statistics
27.605
-1.95 (-6.61%)
The current stock price of MRNA is 27.605 USD. In the past month the price decreased by -9.46%. In the past year, price decreased by -68.12%.
MRNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.43 | 344.84B | ||
| AMGN | AMGEN INC | 14.3 | 159.64B | ||
| GILD | GILEAD SCIENCES INC | 14.62 | 140.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.67B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.61 | 60.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 52.39B | ||
| ARGX | ARGENX SE - ADR | 72.69 | 41.24B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.67 | 32.36B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.80B | ||
| INSM | INSMED INC | N/A | 20.62B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.10B | ||
| BIIB | BIOGEN INC | 8.24 | 19.33B |
Related stock screener links
About MRNA
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Stephane Bancel
Employees: 5800
Phone: 16177146500
MODERNA INC / MRNA FAQ
What is the stock price of MODERNA INC today?
The current stock price of MRNA is 27.605 USD. The price decreased by -6.61% in the last trading session.
What is the ticker symbol for MODERNA INC stock?
The exchange symbol of MODERNA INC is MRNA and it is listed on the Nasdaq exchange.
On which exchange is MRNA stock listed?
MRNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MODERNA INC stock?
31 analysts have analysed MRNA and the average price target is 47.74 USD. This implies a price increase of 72.93% is expected in the next year compared to the current price of 27.605. Check the MODERNA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MODERNA INC worth?
MODERNA INC (MRNA) has a market capitalization of 10.68B USD. This makes MRNA a Large Cap stock.
How many employees does MODERNA INC have?
MODERNA INC (MRNA) currently has 5800 employees.
What are the support and resistance levels for MODERNA INC (MRNA) stock?
MODERNA INC (MRNA) has a support level at 23.64 and a resistance level at 27.61. Check the full technical report for a detailed analysis of MRNA support and resistance levels.
Is MODERNA INC (MRNA) expected to grow?
The Revenue of MODERNA INC (MRNA) is expected to decline by -34.97% in the next year. Check the estimates tab for more information on the MRNA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MODERNA INC (MRNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MRNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MRNA, evaluating the profitability, health, valuation and growth aspects
- MODERNA INC (MRNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MODERNA INC (MRNA) Sales and EPS estimates to see what analysts future expectations are.
- MODERNA INC (MRNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MODERNA INC (MRNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- MODERNA INC (MRNA) Stock Chart to make your own analysis
- MODERNA INC (MRNA) Latest news and press-releases to stay up to date.
Does MODERNA INC (MRNA) stock pay dividends?
MRNA does not pay a dividend.
When does MODERNA INC (MRNA) report earnings?
MODERNA INC (MRNA) will report earnings on 2025-08-01, before the market open.
What is the Price/Earnings (PE) ratio of MODERNA INC (MRNA)?
MODERNA INC (MRNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.73).
What is the Short Interest ratio of MODERNA INC (MRNA) stock?
The outstanding short interest for MODERNA INC (MRNA) is 18.47% of its float. Check the ownership tab for more information on the MRNA short interest.
MRNA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MRNA. When comparing the yearly performance of all stocks, MRNA is a bad performer in the overall market: 93.64% of all stocks are doing better.
MRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MRNA. While MRNA seems to be doing ok healthwise, there are quite some concerns on its profitability.
MRNA Financial Highlights
Over the last trailing twelve months MRNA reported a non-GAAP Earnings per Share(EPS) of -8.73. The EPS increased by 44.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.42% | ||
| ROE | -33.35% | ||
| Debt/Equity | 0 |
MRNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 56% to MRNA. The Buy consensus is the average rating of analysts ratings from 31 analysts.
For the next year, analysts expect an EPS growth of -11.41% and a revenue growth -34.97% for MRNA